TREATMENT OF RELAPSING AND REFRACTORY ADULT ACUTE MYELOID-LEUKEMIA ACCORDING TO IN-VITRO CLONOGENIC LEUKEMIC-CELL DRUG-SENSITIVITY

被引：7

作者：

DELMER, A

MARIE, JP

THEVENIN, D

SUBERVILLE, AM

ZITTOUN, R

机构：

[1] Service d'Hematologie et Laboratoire de Culture et de Cinetique Cellulaires, Paris, Hotel-Dieu

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 10卷 / 1-2期

关键词：

ACUTE MYELOID LEUKEMIA; CLONOGENIC ASSAY; DRUG SENSITIVITY; CHEMOTHERAPY;

D O I：

10.3109/10428199309147358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In an attempt to improve the results of treatment in patients with relapsing or refractory acute myeloid leukemia (AML), we conducted a pilot study using a two-drug salvage regimen according to the in vitro clonogenic leukemic cell (CFU-L) drug sensitivity. Fourteen patients were included in the study, 10 with relapsing and 4 with refractory AML. Drug exposure was assessed for daunorubicin, cytosine arabinoside, etoposide, mitoxantrone and amsacrine. The two drugs with the best inhibitory effect on CFU-L were selected for the treatment. A complete remission was achieved in only 4 patients and a partial remission in 3 patients. Although the number of patients is too small for appropriate statistical analysis and for a definite conclusion to be drawn, the observed response rate with directed therapy did not appear better than that expected from empiric salvage regimen.

引用

页码：67 / 71

页数：5

共 20 条

[1]

Rees J.K.H., Gray R.G., Swinsky D., Hayhoe F.G.J., Principal results of the Medical Research Council's 8th acute myeloid leukemia trial, Lancet, II, pp. 1236-1240, (1986)

[2]

Lihou M.G., Smith P.J., Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level, Cancer Chemolher. Pharmacol., 14, pp. 116-119, (1985)

[3]

Marie J.P., Zittoun R., Delmer A., Thevenin D., Suberville A.M., Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia, Leukemia, 1, pp. 121-126, (1987)

[4]

Preisler H.D., Azarnia N., Assessment of the drug sensitivity of non lymphocytic leukemia using the in vitro assay, Br. J. Haematoi, 58, pp. 633-640, (1984)

[5]

Minden M.D., Buick R.N., McCulloch E.A., Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloid leukemia, Blood, 54, pp. 186-195, (1979)

[6]

Marie J.P., Zittoun R., Thevenin D., Mathieu M., Viguie F., In vitro culture of clonogenic leukaemic cells in acute myelogenous leukaemia: growth pattern and drug sensitivity, Br. J. Haematoi., 55, pp. 427-437, (1983)

[7]

Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., Brunning R., Gale R.P., Grever M.R., Keating M.J., Sawitsky A., Stass S., Weinstein H., Woods W.G., Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia, J. Clin. Oncol., 8, pp. 813-819, (1990)

[8]

Veerman A.J.P., Pieters R., Drug sensitivity assays in leukaemia and lymphoma, Br. J. Haematol, 74, pp. 381-384, (1990)

[9]

Park C.H., Wiemik P.J., Morrison F.S., Amare M., Van Sloten K., Maloney T.R., Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drug, Cancer Res., 43, pp. 2346-2349, (1983)

[10]

Gustavsson A., Olofsson T., Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells, Cancer Res., 44, pp. 4648-4652, (1984)

← 1 2 →